{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:13:25Z","timestamp":1791922405104,"version":"4.3.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20Y11914300"],"award-info":[{"award-number":["20Y11914300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The clinical management of advanced thyroid carcinoma presents substantial therapeutic challenges due to non-curative surgical outcomes and resistance to both radioiodine therapy and conventional chemotherapeutic agents. Emerging evidence implicates copper dysregulation in thyroid cancer pathogenesis, yet monotherapy with copper ionophores demonstrates constrained efficacy due to tumor-intrinsic adaptive resistance mechanisms. In this study, we investigated the therapeutic potential of combining Sunitinib with copper ionophore Elesclomol as a novel strategy against thyroid carcinoma. Mechanically, we identified that Sunitinib treatment induces ROS accumulation, activating the stress-responsive transcription factor ATF3, which directly binds and transactivates the copper transporter gene SLC31A1. Clinically, TCGA analysis reveals SLC31A1 as a vulnerability in advanced thyroid cancer, with expression significantly downregulated in metastatic lesions, a deficit rescued by Sunitinib. Overall, these results demonstrate that Sunitinib and copper ionophores can induce synergistic cytotoxic effect, shedding light on therapeutic strategy for advanced thyroid carcinomas.<\/jats:p>","DOI":"10.1038\/s41419-026-08878-9","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T10:14:47Z","timestamp":1780308887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Sunitinib enhances cuproptosis induced by copper ionophores via ROS-ATF3-SLC31A1 axis in thyroid Carcinoma"],"prefix":"10.1038","volume":"17","author":[{"given":"Dan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3072-271X","authenticated-orcid":false,"given":"Zhou","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangze","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-7948","authenticated-orcid":false,"given":"Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6110-8844","authenticated-orcid":false,"given":"Jun","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"8878_CR1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s11154-023-09818-0","volume":"25","author":"F Pitoia","year":"2024","unstructured":"Pitoia F, Scheffel RS, Califano I, Gauna A, Tala H, Vaisman F, et al. Management of radioiodine refractory differentiated thyroid cancer: the Latin American perspective. Rev Endocr Metab Disord. 2024;25:109\u201321.","journal-title":"Rev Endocr Metab Disord"},{"key":"8878_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100939","volume":"68","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang J, Hu X, Pan Z, Xu T, Xu J, et al. Radioiodine therapy in advanced differentiated thyroid cancer: resistance and overcoming strategy. Drug Resist Updat. 2023;68:100939.","journal-title":"Drug Resist Updat"},{"key":"8878_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/ERC-20-0106","volume":"28","author":"C Sparano","year":"2021","unstructured":"Sparano C, Godbert Y, Attard M, Do Cao C, Zerdoud S, Roudaut N, et al. Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. Endocr Relat Cancer. 2021;28:15\u201326.","journal-title":"Endocr Relat Cancer"},{"key":"8878_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1053\/j.seminoncol.2018.11.004","volume":"46","author":"ME Cabanillas","year":"2019","unstructured":"Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol. 2019;46:57\u201364.","journal-title":"Semin Oncol"},{"key":"8878_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.592202","volume":"10","author":"A Porter","year":"2020","unstructured":"Porter A, Wong DJ. Perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions. Front Oncol. 2020;10:592202.","journal-title":"Front Oncol"},{"key":"8878_CR6","doi-asserted-by":"crossref","unstructured":"Xie J, Liu J, Zhao M, Li X, Wang Y, Zhao Y, et al. Disulfiram\/Cu kills and sensitizes BRAF-mutant thyroid cancer cells to BRAF kinase inhibitor by ROS-dependently relieving feedback activation of MAPK\/ERK and PI3K\/AKT pathways. Int J Mol Sci. 2023;24:3418.","DOI":"10.3390\/ijms24043418"},{"key":"8878_CR7","first-page":"718","volume":"113","author":"F Kosova","year":"2012","unstructured":"Kosova F, Cetin B, Akinci M, Aslan S, Seki A, Pirhan Y, et al. Serum copper levels in benign and malignant thyroid diseases. Bratisl Lek Listy. 2012;113:718\u201320.","journal-title":"Bratisl Lek Listy"},{"key":"8878_CR8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1385\/BTER:93:1-3:9","volume":"93","author":"M Kucharzewski","year":"2003","unstructured":"Kucharzewski M, Braziewicz J, Majewska U, G\u00f3zdz S. Copper, zinc, and selenium in whole blood and thyroid tissue of people with various thyroid diseases. Biol Trace Elem Res. 2003;93:9\u201318.","journal-title":"Biol Trace Elem Res"},{"key":"8878_CR9","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1126\/science.abf0529","volume":"375","author":"P Tsvetkov","year":"2022","unstructured":"Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375:1254\u201361.","journal-title":"Science"},{"key":"8878_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01732-y","volume":"22","author":"J Xie","year":"2023","unstructured":"Xie J, Yang Y, Gao Y, He J. Cuproptosis: mechanisms and links with cancers. Mol Cancer. 2023;22:46.","journal-title":"Mol Cancer"},{"key":"8878_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41392-022-01229-y","volume":"7","author":"L Chen","year":"2022","unstructured":"Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther. 2022;7:378.","journal-title":"Signal Transduct Target Ther"},{"key":"8878_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102891","volume":"67","author":"J Gao","year":"2023","unstructured":"Gao J, Wu X, Huang S, Zhao Z, He W, Song M. Novel insights into anticancer mechanisms of elesclomol: more than a prooxidant drug. Redox Biol. 2023;67:102891.","journal-title":"Redox Biol"},{"key":"8878_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/imr.13276","volume":"321","author":"WQ Liu","year":"2024","unstructured":"Liu WQ, Lin WR, Yan L, Xu WH, Yang J. Copper homeostasis and cuproptosis in cancer immunity and therapy. Immunol Rev. 2024;321:211\u201327.","journal-title":"Immunol Rev"},{"key":"8878_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202309984","volume":"11","author":"X Lu","year":"2024","unstructured":"Lu X, Chen X, Lin C, Yi Y, Zhao S, Zhu B, et al. Elesclomol loaded copper oxide nanoplatform triggers cuproptosis to enhance antitumor immunotherapy. Adv Sci (Weinh). 2024;11:e2309984.","journal-title":"Adv Sci (Weinh)"},{"key":"8878_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ygyno.2018.10.001","volume":"151","author":"BJ Monk","year":"2018","unstructured":"Monk BJ, Kauderer JT, Moxley KM, Bonebrake AJ, Dewdney SB, Secord AA, et al. A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology\/gynecologic oncology group study. Gynecol Oncol. 2018;151:422\u20137.","journal-title":"Gynecol Oncol"},{"key":"8878_CR16","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrm.2016.87","volume":"17","author":"M Simons","year":"2016","unstructured":"Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial VEGF receptor signalling. Nat Rev Mol Cell Biol. 2016;17:611\u201325.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8878_CR17","doi-asserted-by":"crossref","unstructured":"Enokida T, Tahara M. Management of VEGFR-targeted TKI for thyroid cancer. Cancers (Basel). 2021;13:5536.","DOI":"10.3390\/cancers13215536"},{"key":"8878_CR18","doi-asserted-by":"publisher","first-page":"C186","DOI":"10.1152\/ajpcell.00132.2018","volume":"315","author":"T Fukai","year":"2018","unstructured":"Fukai T, Ushio-Fukai M, Kaplan JH. Copper transporters and copper chaperones: roles in cardiovascular physiology and disease. Am J Physiol Cell Physiol. 2018;315:C186\u2013c201.","journal-title":"Am J Physiol Cell Physiol"},{"key":"8878_CR19","doi-asserted-by":"publisher","first-page":"e71982","DOI":"10.1371\/journal.pone.0071982","volume":"8","author":"G Narayanan","year":"2013","unstructured":"Narayanan G, Vuyyuru RBS, Muthuvel H, Konerirajapuram Natrajan B. S. CTR1 silencing inhibits angiogenesis by limiting copper entry into endothelial cells. PLoS One. 2013;8:e71982.","journal-title":"PLoS One"},{"key":"8878_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1753-4887.2004.tb00025.x","volume":"62","author":"ED Harris","year":"2004","unstructured":"Harris ED. A requirement for copper in angiogenesis. Nutr Rev. 2004;62:60\u20134.","journal-title":"Nutr Rev"},{"key":"8878_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41556-021-00822-7","volume":"24","author":"A Das","year":"2022","unstructured":"Das A, Ash D, Fouda AY, Sudhahar V, Kim YM, Hou Y, et al. Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesis. Nat Cell Biol. 2022;24:35\u201350.","journal-title":"Nat Cell Biol"},{"key":"8878_CR22","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharm Rev. 2006;58:621\u201381.","journal-title":"Pharm Rev"},{"key":"8878_CR23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41568-021-00417-2","volume":"22","author":"EJ Ge","year":"2022","unstructured":"Ge EJ, Bush AI, Casini A, Cobine PA, Cross JR, DeNicola GM, et al. Connecting copper and cancer: from transition metal signalling to metalloplasia. Nat Rev Cancer. 2022;22:102\u201313.","journal-title":"Nat Rev Cancer"},{"key":"8878_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.698167","volume":"8","author":"LS Kazi Tani","year":"2021","unstructured":"Kazi Tani LS, Gourlan AT, Dennouni-Medjati N, Telouk P, Dali-Sahi M, Harek Y, et al. Copper isotopes and copper to zinc ratio as possible biomarkers for thyroid cancer. Front Med (Lausanne). 2021;8:698167.","journal-title":"Front Med (Lausanne)"},{"key":"8878_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-018-0645-x","volume":"11","author":"M Si","year":"2018","unstructured":"Si M, Lang J. The roles of metallothioneins in carcinogenesis. J Hematol Oncol. 2018;11:107.","journal-title":"J Hematol Oncol"},{"key":"8878_CR26","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1080\/13543784.2016.1242577","volume":"25","author":"JM G\u00f3mez-S\u00e1ez","year":"2016","unstructured":"G\u00f3mez-S\u00e1ez JM. Sunitinib for the treatment of thyroid cancer. Expert Opin Investig Drugs. 2016;25:1345\u201352.","journal-title":"Expert Opin Investig Drugs"},{"key":"8878_CR27","doi-asserted-by":"publisher","first-page":"5260","DOI":"10.1158\/1078-0432.CCR-10-0994","volume":"16","author":"LL Carr","year":"2010","unstructured":"Carr LL, Mankoff DA, Goulart BH, Eaton KD, Capell PT, Kell EM, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16:5260\u20138.","journal-title":"Clin Cancer Res"},{"key":"8878_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06121-1","volume":"23","author":"Y Cong","year":"2025","unstructured":"Cong Y, Li N, Zhang Z, Shang Y, Zhao H. Cuproptosis: molecular mechanisms, cancer prognosis, and therapeutic applications. J Transl Med. 2025;23:104.","journal-title":"J Transl Med"},{"key":"8878_CR29","doi-asserted-by":"crossref","unstructured":"Huo S, Wang Q, Shi W, Peng L, Jiang Y, Zhu M, et al. ATF3\/SPI1\/SLC31A1 Signaling promotes cuproptosis induced by advanced glycosylation end products in diabetic myocardial injury. Int J Mol Sci. 2023;24:1667.","DOI":"10.3390\/ijms24021667"},{"key":"8878_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13046-018-0919-8","volume":"37","author":"C Chen","year":"2018","unstructured":"Chen C, Ge C, Liu Z, Li L, Zhao F, Tian H, et al. ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression. J Exp Clin Cancer Res. 2018;37:263.","journal-title":"J Exp Clin Cancer Res"},{"key":"8878_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jconrel.2023.12.038","volume":"366","author":"X Zhao","year":"2024","unstructured":"Zhao X, Wang Z, Wu G, Yin L, Xu L, Wang N, et al. Apigenin-7-glucoside-loaded nanoparticle alleviates intestinal ischemia-reperfusion by ATF3\/SLC7A11-mediated ferroptosis. J Control Release. 2024;366:182\u201393.","journal-title":"J Control Release"},{"key":"8878_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/tox.23857","volume":"39","author":"R Bi","year":"2024","unstructured":"Bi R, Hu R, Jiang L, Wen B, Jiang Z, Liu H, et al. Butyrate enhances erastin-induced ferroptosis of lung cancer cells via modulating the ATF3\/SLC7A11 pathway. Environ Toxicol. 2024;39:529\u201338.","journal-title":"Environ Toxicol"},{"key":"8878_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103118","volume":"71","author":"J Liu","year":"2024","unstructured":"Liu J, Lu X, Zeng S, Fu R, Wang X, Luo L, et al. ATF3-CBS signaling axis coordinates ferroptosis and tumorigenesis in colorectal cancer. Redox Biol. 2024;71:103118.","journal-title":"Redox Biol"},{"key":"8878_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01617-7","volume":"22","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Xu T, Xie J, Wu H, Hu W, Yuan X. MSC-derived mitochondria promote axonal regeneration via Atf3 gene up-regulation by ROS induced DNA double strand breaks at transcription initiation region. Cell Commun Signal. 2024;22:240.","journal-title":"Cell Commun Signal"},{"key":"8878_CR35","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1158\/1078-0432.CCR-23-3417","volume":"30","author":"JD French","year":"2024","unstructured":"French JD, Haugen BR, Worden FP, Bowles DW, Gianoukakis AG, Konda B, et al. Combination targeted therapy with pembrolizumab and lenvatinib in progressive, radioiodine-refractory differentiated thyroid cancers. Clin Cancer Res. 2024;30:3757\u201367.","journal-title":"Clin Cancer Res"},{"key":"8878_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ecl.2018.10.009","volume":"48","author":"SP Weitzman","year":"2019","unstructured":"Weitzman SP, Sherman SI. Novel drug treatments of progressive radioiodine-refractory differentiated thyroid cancer. Endocrinol Metab Clin North Am. 2019;48:253\u201368.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"8878_CR37","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/cen.13508","volume":"88","author":"ML Gild","year":"2018","unstructured":"Gild ML, Topliss DJ, Learoyd D, Parnis F, Tie J, Hughes B, et al. Clinical guidance for radioiodine refractory differentiated thyroid cancer. Clin Endocrinol (Oxf). 2018;88:529\u201337.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"8878_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2217\/nnm-2021-0374","volume":"17","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Huo Z, Qi X, Zuo T, Wu Z. Copper-induced tumor cell death mechanisms and antitumor theragnostic applications of copper complexes. Nanomed (Lond). 2022;17:303\u201324.","journal-title":"Nanomed (Lond)"},{"key":"8878_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1582-4934.2003.tb00198.x","volume":"7","author":"GJ Brewer","year":"2003","unstructured":"Brewer GJ. Tetrathiomolybdate anticopper therapy for Wilson\u2019s disease inhibits angiogenesis, fibrosis and inflammation. J Cell Mol Med. 2003;7:11\u201320.","journal-title":"J Cell Mol Med"},{"key":"8878_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-44681-8","volume":"13","author":"Y Qi","year":"2023","unstructured":"Qi Y, Yao Q, Li X, Li X, Zhang W, Qu P. Cuproptosis-related gene SLC31A1: prognosis values and potential biological functions in cancer. Sci Rep. 2023;13:17790.","journal-title":"Sci Rep"},{"key":"8878_CR41","first-page":"995","volume":"52","author":"Y Cai","year":"2023","unstructured":"Cai Y, Niu B, Gao J, Su H. Potential role of cuproptosis-related Lncrna in prognosis and immunotherapy of thyroid carcinoma. Iran J Public Health. 2023;52:995\u20131007.","journal-title":"Iran J Public Health"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08878-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08878-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:30:58Z","timestamp":1785810658000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08878-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8878"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08878-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"11 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments were approved by the Committee on the Ethics of Animal Experiments of Fudan University Shanghai Cancer Center (FUSCC-IACUC-2024529). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"681"}}